| Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating … JR Bailey, AR Sedaghat, T Kieffer, T Brennan, PK Lee, M Wind-Rotolo, ... Journal of virology 80 (13), 6441-6457, 2006 | 501 | 2006 |
| Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors JN Blankson, JR Bailey, S Thayil, HC Yang, K Lassen, J Lai, SK Gandhi, ... Journal of virology 81 (5), 2508-2518, 2007 | 343 | 2007 |
| Maintenance of viral suppression in HIV-1–infected HLA-B*57+ elite suppressors despite CTL escape mutations JR Bailey, TM Williams, RF Siliciano, JN Blankson The Journal of experimental medicine 203 (5), 1357-1369, 2006 | 340 | 2006 |
| Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses WO Osburn, AE Snider, BL Wells, R Latanich, JR Bailey, DL Thomas, ... Hepatology 59 (6), 2140-2151, 2014 | 283 | 2014 |
| Nuclear Retention of Multiply Spliced HIV-1 RNA in Resting CD4+ T Cells KG Lassen, KX Ramyar, JR Bailey, Y Zhou, RF Siliciano PLoS pathogens 2 (7), e68, 2006 | 243 | 2006 |
| Approaches, progress, and challenges to hepatitis C vaccine development JR Bailey, E Barnes, AL Cox Gastroenterology 156 (2), 418-430, 2019 | 237 | 2019 |
| Neutralizing antibodies do not mediate suppression of human immunodeficiency virus type 1 in elite suppressors or selection of plasma virus variants in patients on highly … JR Bailey, KG Lassen, HC Yang, TC Quinn, SC Ray, JN Blankson, ... Journal of virology 80 (10), 4758-4770, 2006 | 223 | 2006 |
| Analysis of Human Immunodeficiency Virus Type 1 Transcriptional Elongation in Resting CD4+ T Cells In Vivo KG Lassen, JR Bailey, RF Siliciano Journal of virology 78 (17), 9105-9114, 2004 | 198 | 2004 |
| Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance SA Rabi, GM Laird, CM Durand, S Laskey, L Shan, JR Bailey, S Chioma, ... The Journal of clinical investigation 123 (9), 3848-3860, 2013 | 182 | 2013 |
| Elucidating the elite: mechanisms of control in HIV-1 infection KA O’Connell, JR Bailey, JN Blankson Trends in pharmacological sciences 30 (12), 631-637, 2009 | 151 | 2009 |
| Control of HIV-1 in elite suppressors despite ongoing replication and evolution in plasma virus KA O'Connell, TP Brennan, JR Bailey, SC Ray, RF Siliciano, JN Blankson Journal of virology 84 (14), 7018-7028, 2010 | 138 | 2010 |
| Transmission of human immunodeficiency virus type 1 from a patient who developed AIDS to an elite suppressor JR Bailey, K O'Connell, HC Yang, Y Han, J Xu, B Jilek, TM Williams, ... Journal of virology 82 (15), 7395-7410, 2008 | 138 | 2008 |
| Broadly neutralizing antibodies with few somatic mutations and hepatitis C virus clearance JR Bailey, AI Flyak, VJ Cohen, H Li, LN Wasilewski, AE Snider, S Wang, ... JCI insight 2 (9), 2017 | 126 | 2017 |
| Elite suppressor–derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics KG Lassen, MA Lobritz, JR Bailey, S Johnston, S Nguyen, B Lee, T Chou, ... PLoS pathogens 5 (4), e1000377, 2009 | 120 | 2009 |
| Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV JA Ruddy, BJ Boyarsky, JR Bailey, AH Karaba, JM Garonzik-Wang, ... Aids 35 (14), 2399-2401, 2021 | 112* | 2021 |
| HCV broadly neutralizing antibodies use a CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design AI Flyak, S Ruiz, MD Colbert, T Luong, JE Crowe, JR Bailey, PJ Bjorkman Cell host & microbe 24 (5), 703-716. e3, 2018 | 107 | 2018 |
| Role of APOBEC3G/F-mediated hypermutation in the control of human immunodeficiency virus type 1 in elite suppressors SK Gandhi, JD Siliciano, JR Bailey, RF Siliciano, JN Blankson Journal of virology 82 (6), 3125-3130, 2008 | 103 | 2008 |
| Durable SARS-CoV-2 B cell immunity after mild or severe disease CO Ogega, NE Skinner, PW Blair, HS Park, K Littlefield, A Ganesan, ... The Journal of clinical investigation 131 (7), 2021 | 100 | 2021 |
| A third dose of SARS‐CoV‐2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients AH Karaba, X Zhu, T Liang, KH Wang, AG Rittenhouse, O Akinde, Y Eby, ... American Journal of Transplantation 22 (4), 1253-1260, 2022 | 96 | 2022 |
| Naturally selected hepatitis C virus polymorphisms confer broad neutralizing antibody resistance JR Bailey, LN Wasilewski, AE Snider, R El-Diwany, WO Osburn, Z Keck, ... The Journal of clinical investigation 125 (1), 437-447, 2015 | 94 | 2015 |
